References

The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis

10.1007/s12016-018-8702-3 · 2018 · External reference

Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability

10.1016/j.immuni.2015.09.003 · 2015 · External reference

Paradoxical gastrointestinal effects of interleukin-17 blockers

10.1136/annrheumdis-2020-217927 · 2020 · External reference

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

10.1136/gutjnl-2011-301668 · 2012 · External reference

A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn's disease

10.1038/ajg.2016.298 · 2016 · External reference

Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials

10.1136/annrheumdis-2018-214273 · 2019 · External reference

Systematic review with meta-analysis: risk of new onset IBD with the use of anti-interleukin-17 agents

10.1111/apt.15397 · 2019 · External reference

Risk for development of inflammatory bowel disease under inhibition of interleukin 17: a systematic review and meta-analysis

10.1371/journal.pone.0233781 · 2020 · External reference

Risk of new-onset inflammatory bowel disease in psoriasis patients treated with five different interleukin inhibitors: a systematic review and meta-analysis

10.3389/fimmu.2025.1594998 · 2025 · External reference

Vunakizumab for IL-17A-mediated diseases: a review in psoriasis and spondyloarthritis

10.2147/btt.s500475 · 2026 · External reference

Structure and signalling in the IL-17 receptor family

10.1038/nri2586 · 2009 · External reference

Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease

10.1111/j.1365-2567.2009.03240.x · 2010 · External reference

New onset severe ulcerative colitis following ixekizumab therapy

10.22551/2022.37.0904.10227 · 2022 · External reference

Severe drug-associated colitis with Crohn's features in setting of ixekizumab therapy for chronic plaque psoriasis

10.1186/s12876-021-01936-w · 2021 · External reference

Rapid onset of inflammatory bowel disease after receiving secukinumab infusion

10.14309/crj.2018.56 · 2018 · External reference

The onset of ulcerative colitis during treatment with secukinumab: can anti-IL-17A be a trigger for inflammatory bowel disease?

10.17235/reed.2019.5841/2018 · 2019 · External reference

IL-17A inhibitor-induced ulcerative colitis treated with an anti-IL-23 antibody

10.1007/s12328-025-02153-8 · 2025 · External reference

Emergence of inflammatory bowel disease during treatment with secukinumab

10.1093/ecco-jcc/jjy063 · 2018 · External reference

Crohn's-like disease in a patient exposed to anti-interleukin-17 blockade (ixekizumab) for the treatment of chronic plaque psoriasis: a case report

10.1186/s12876-019-1067-0 · 2019 · External reference

Secukinumab-induced inflammatory bowel disease in a patient treated for chronic plaque psoriasis and psoriatic arthritis: a case report and review of the role of novel biologic agents targeting the p19 subunit of IL-23

10.1155/2020/9404505 · 2020 · External reference

New-onset Crohn's disease following initiation of secukinumab: a case report and review of the role of IL-17 in the pathogenesis of Crohn's disease

10.1155/2023/1769290 · 2023 · External reference

Colitis induced by IL-17A-inhibitors

10.1007/s12328-023-01893-9 · 2023 · External reference

New-onset, treatment-resistant inflammatory bowel disease after administration of secukinumab for plaque psoriasis: a case report and review of the existing literature

10.31138/mjr.030124.ntt · 2024 · External reference

Case report: secukinumab (interleukin-17 inhibitor) and ulcerative colitis flare-the double-edged sword

10.1159/000547522 · 2025 · External reference

New onset inflammatory bowel disease after initiation of anti-IL-17A treatment: a case series

10.51821/87.3.12874 · 2024 · External reference

Shared Pathophysiology of Inflammatory Bowel Disease and Psoriasis: Unraveling the Connection

10.7759/cureus.70148 · 2024 · External reference